Results

Grifols SA

07/30/2021 | Press release | Distributed by Public on 07/30/2021 05:43

Sequential Page Number (Form 6-K)

Sequential Page Number
1. Other Relevant Information dated July 30, 2021 3
Grifols, S.A.

Avinguda de la Generalitat 152-158

08174 Sant Cugat del Vallès

Barcelona - ESPAÑA

Tel. [34] 935 710 500
Fax [34] 935 710 267
www.grifols.com

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ('Grifols') hereby informs about the following

OTHER RELEVANT INFORMATION

Grifols informs that it has signed an arrangement whereby, with the collaboration of the US company ImmunoTek Bio Centers LLC, it will develop 21 new plasma collection centers in the United States to exclusively serve its manufacturing needs. Grifols will fund such development and the expectation is that all 21 plasma collection centers will be operating by October 2022. All centers will be licensed by the U.S. Food and Drug Administration (FDA) and the European Authorities. 5 of the 21 plasma collection centers are already operating and are currently in the ramp-up phase. When ramped-up, the 21 plasma collection centers are expected to collect in the aggregate 1 million liters of plasma annually.

In Barcelona, on 30 July 2021
Nuria Martín Barnés
Secretary to the Board of Directors